Orca Bio

@OrcaBio

Transforming allogeneic cell therapy for patients with blood cancer and autoimmune diseases

Menlo Park, CA

Joined April 2018

Orca Bio
@OrcaBio
Jul 27
As we move into the second half of 2026, we’re energized by all #TeamOrcaBio has accomplished this year, including our first U.S. FDA approval. We’re looking forward to building on this momentum as we continue to advance our high-precision cell therapies for patients.
00:00
Orca Bio
@OrcaBio
Jul 16
Advancing care for patients requires strong advocacy across the healthcare community. We are grateful to organizations like the @MDSFoundation that provide critical education, advocacy and support for patients and families affected by myelodysplastic syndromes. #PatientsFirst
Orca Bio
@OrcaBio
Jul 9
Chronic graft versus host disease (#GVHD) remains a potentially serious complication after allogeneic stem cell transplant. Learn more about results from the pivotal Phase 3 Precision-T trial which supported the U.S. FDA approval of our precision-engineered cell
Orca Bio
@OrcaBio
Jul 7
Following last week’s FDA approval, we are officially stepping into an exciting new chapter. We want to express our gratitude to the patients, providers, advocates and everyone at #TeamOrcaBio who made the approval of our precision-engineered cell therapy for allogeneic
Orca Bio
@OrcaBio
Jun 30
We are proud to announce the U.S. FDA approval of our new precision-engineered cell therapy for allogeneic transplant in people with hematologic malignancies. This marks a significant milestone for Orca Bio, and most importantly, for the patients we serve. Learn
00:00